Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma

Tirumani, Sree Harsha; LaCasce, Ann S.; Jacene, Heather A.

doi:10.1016/j.cpet.2014.12.005

Cited by 11 publications

(6 citation statements)

References 114 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is supported by the fact that the majority of the patients had a history of malignancy or had been diagnosed with malignancy on the diagnosis of IgG4‐RD, and that many patients with IgG4‐RD had multiple organ involvement and lymphomas. Currently, patients with malignancy, especially lymphoma, require routine PET/CT imaging for disease staging and predicting the prognosis . Therefore, it might be reasonable to perform PET/CT in patients with IgG4‐RD.…”

Section: Discussionmentioning

confidence: 99%

Malignancies in Korean patients with immunoglobulin G4‐related disease

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Malignancies in Korean patients with immunoglobulin G4‐related disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…PET imaging is progressively being incorporated for staging and response assessment in a number of malignancies ( e.g. , lymphoma) [ 38 ]. In the context of GEP-NETs, however, it would be only applicable to highly proliferative or poorly differentiated tumors, as guidelines have been specifically developed for the 18 FDG radionuclide.…”

Section: Imaging Assessment Of Tumor Responsementioning

confidence: 99%

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

Garcia-Carbonero¹,

García‐Figueiras

Carmona-Bayonas

et al. 2015

Cancer Metastasis Rev

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a family of neoplasms with a complex spectrum of clinical behavior. Although generally more indolent than carcinomas, once they progress beyond surgical resectability, they are essentially incurable. Systemic treatment options have substantially expanded in recent years for the management of advanced disease. Imaging plays a major role in new drug development, as it is the main tool used to objectively evaluate response to novel agents. However, current standard response criteria have proven suboptimal for the assessment of the antiproliferative effect of many targeted agents, particularly in the context of slow-growing tumors such as well-differentiated NETs. The aims of this article are to discuss the advantages and limitations of conventional radiological techniques and standard response assessment criteria and to review novel imaging modalities in development as well as alternative cancer- and therapy-specific criteria to assess drug efficacy in the field of GEP-NETs.

show abstract

“…Tirumani et al had reported excellent results for PET/ CT in the initial assessment of lymphoma and is considered as a more accurate modality for detection of recurrence/residual lesions than the standard anatomical imaging modalities [11].…”

Section: Discussionmentioning

confidence: 99%

Role of fused PET/CT compared to the standard contrast-enhanced CT in the follow-up assessment of the treated gastric malignancy

Baz

Hassan

2019

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background: To investigate the use of fused positron emission tomography/computed tomography (PET/CT) compared to contrast-enhanced computed tomography (CECT) in the follow-up of treated gastric malignancies, all data were collected and analyzed retrospectively, enrolling 68 patients (18 females and 50 males) (their age range = 34-73 years). The patients had been referred to a private imaging center for their assessment by PET/CT. Results: Adenocarcinoma was present in 73.5%, lymphoma was present in 23.5%, and malignant carcinoid was found in 3% of cases. All patients had received at least one treatment method including endoscopic/surgical resection, chemotherapy, and radiotherapy. By PET/CT, gastric recurrence/residual was depicted in 30 patients (47.0%) compared 46 patients (67.5%) as detected by CECT, and this was statistically significant (P value = 0.006), nodal metastasis was present in 18 patients (26.5%) compared to 26 patients (38%) as detected by CECT (P value = 0.143), and distant metastasis was present in 18 patients (26.5%) compared to 24 patients (35%) as depicted by CECT (P value = 0.265). Conclusion: PET/CT offered a useful diagnostic modality as compared to CECT for follow-up evaluation of cases with treated gastric malignancies through a precise detection of the gastric lesions but it had rather comparable results in the detection of nodal and distant metastases.

show abstract

Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma

Cited by 11 publications

References 114 publications

Malignancies in Korean patients with immunoglobulin G4‐related disease

Malignancies in Korean patients with immunoglobulin G4‐related disease

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

Role of fused PET/CT compared to the standard contrast-enhanced CT in the follow-up assessment of the treated gastric malignancy

Contact Info

Product

Resources

About